Christopher John Kenney

Executive

Insider activity · 24 months0 buys2 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 2 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (3 ops.)

€281k

Latest filing published 01 Sept 2026 for Xenon Pharmaceuticals Inc., €26k.

Filing timeline

BuySale

Christopher John Kenney

Insider track record

Disclosed buys

Disclosed sells

Signal history

Christopher John Kenney: trading record in brief

Christopher John Kenney appears in our data through filings on Xenon Pharmaceuticals Inc. shares, published by SEC (Form 4). Over a trading history stretching from 24 March 2023 to 28 August 2026, the count stands at 5 filings.

The open-market record consists of 3 sales worth €281k, with no purchase. The rest of the record consists of 1 share grant and 1 option exercise. So far in 2026, the count stands at no purchases and 2 sales.

Most recently, on 1 September 2026, the filings show an open-market sale worth €26k in Xenon Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.